Back to search results

Phase 2 Study of Nivolumab Plus AVD for Hodgkin Lymphoma

This study is looking at whether a combination of medicines, nivolumab and AVD (doxorubicin, vinblastine, and dacarbazine), can help children, teenagers, and young adults (ages 2 to 21) who have recently been diagnosed with early-stage Hodgkin lymphoma. Hodgkin lymphoma is a type of cancer that affects the immune system. Researchers want to see how well this combination works to control the cancer and also to understand its safety. The study is currently enrolling about 15 participants. This treatment works by using immunotherapy, which helps your body's immune system fight cancer.

Study design
This is an interventional study with a planned enrollment of 15 participants. It is designed to assess the safety and effectiveness of nivolumab plus AVD.
What's involved
Participants will receive nivolumab, doxorubicin, vinblastine, and dacarbazine intravenously (through a vein) on specific days for two cycles, with each cycle lasting 28 days.
Compensation
Not stated in the trial record.
Follow-up
Safety and side effects will be measured throughout the study, which is expected to last about one year on average.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07551583

Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

Recruiting
PHASE2Ages 2–21InterventionalTreatment
M.D. Anderson Cancer Center
~15 participants
Updated 2026-08-31 on ClinicalTrials.gov
What's tested:NivolumabDoxorubicin HydrochlorideVinblastineDacarbazine

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Hodgkin Lymphoma

Explore related trials

Hodgkin's Granuloma

NCT07551583

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UT MD Anderson

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • David McCall, MD · PRINCIPAL_INVESTIGATOR · UT MD Anderson

Who to contact

David McCall, MD
[email protected]
(713) 792-6604
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Postmenopausal (no menses in greater than or equal to 12 consecutive months).
History of hysterectomy or bilateral salpingo-oophorectomy.
Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
History of bilateral tubal ligation or another surgical sterilization procedure.

What this trial measures

  • Safety and Adverse Events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0